In the second largest oncology acquisition of the year so far, Eli Lilly has agreed to acquire Loxo Oncology in a deal worth up to US$8 B. Lilly will acquire Loxo’s outstanding shares at a price of US$235 per share representing a premium of more than 60%. Loxo specialises in developing and commercialising highly selective cancer therapies targeting underlying genomic abnormalities in tumours rather than the malignancy location. The company’s lead asset, Vitrakvi® (larotrectinib), was approved by the US FDA in November 2018.